Suppr超能文献

组织型纤溶酶原激活剂 - 抗生素封管与肝素 - 抗生素封管在儿童导管相关菌血症中的比较。

Comparison of tissue plasminogen activator-antibiotic locks with heparin-antibiotic locks in children with catheter-related bacteraemia.

作者信息

Onder Ali Mirza, Chandar Jayanthi, Simon Nancy, Diaz Rosa, Nwobi Obioma, Abitbol Carolyn L, Zilleruelo Gaston

机构信息

Division of Paediatric Nephrology, Department of Paediatrics, West Virginia University, WV, USA.

出版信息

Nephrol Dial Transplant. 2008 Aug;23(8):2604-10. doi: 10.1093/ndt/gfn023. Epub 2008 Mar 10.

Abstract

BACKGROUND

An accepted pathogenesis of catheter-related bacteraemia (CRB) is the seeding of microorganisms from the intraluminal biofilm of central venous catheters. Antibiotic locks (ABL) are solutions containing high concentrations of antimicrobials with or without anticoagulants that aim to destroy the biofilm.

METHODS

In this study, two different ABL solutions, tissue plasminogen activator (TPA)-based and heparin-based ABL, used in conjunction with systemic antibiotics, were prospectively compared in the treatment of CRB.

RESULTS

A total of 42 children on chronic haemodialysis with 11,016 catheter-days were observed for signs and symptoms of CRB over a period of 10 months. Twenty-four CRBs were diagnosed in 18 children (2.2 CRB/1000 catheter-days) and were treated with the protocol. Symptoms of CRB resolved in 83% within 48 h of treatment. None of the infected catheters required early emergent exchange or removal for poorly controlled CRB. Six children had recurrence of CRB within 6 weeks, of which four required catheter exchange. There was no specific microorganism or type of CRB that predisposed to higher recurrence rates. The mean infection-free survival of the catheters following TPA-ABL treatment was shorter than that following heparin-ABL treatment, but was not statistically significant by the log-rank test (126.8 +/- 81.6 days versus 154.5 +/- 70.4 days).

CONCLUSION

Both TPA-ABL and heparin-ABL used in conjunction with systemic antibiotics can effectively clear CRB without significant late recurrence at 6 weeks. Early use of ABL for management of CRB can potentially decrease the need for catheter removal, thus salvaging vascular access sites.

摘要

背景

导管相关菌血症(CRB)公认的发病机制是微生物从中心静脉导管腔内生物膜播散。抗生素封管液(ABL)是含有高浓度抗菌药物且可含或不含抗凝剂的溶液,旨在破坏生物膜。

方法

在本研究中,将两种不同的ABL溶液,即基于组织型纤溶酶原激活剂(TPA)的ABL和基于肝素的ABL,与全身抗生素联合使用,对CRB的治疗进行前瞻性比较。

结果

在10个月的时间里,对42例接受慢性血液透析、导管留置天数达11016天的儿童观察CRB的体征和症状。18例儿童诊断出24例CRB(2.2例CRB/1000导管日),并按方案进行治疗。83%的CRB症状在治疗后48小时内缓解。没有一根感染导管因CRB控制不佳而需要早期紧急更换或拔除。6例儿童在6周内CRB复发,其中4例需要更换导管。没有特定的微生物或CRB类型更容易导致更高的复发率。TPA-ABL治疗后导管的平均无感染生存期短于肝素-ABL治疗后,但经对数秩检验无统计学意义(126.8±81.6天对154.5±70.4天)。

结论

TPA-ABL和肝素-ABL与全身抗生素联合使用均可有效清除CRB,6周时无明显晚期复发。早期使用ABL治疗CRB可能减少导管拔除的需求,从而挽救血管通路部位。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验